Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China ...

Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co. -- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in...